Zoetis Secures USDA License for Longer-Acting Cytopoint Plus

What happened

Zoetis announced that Cytopoint Plus has received a USDA license, providing dogs with allergic dermatitis 75 days of itch relief and a longer interval between injections. This strengthens the company's already robust dermatology franchise, which grew 11% operationally in Q2 2025 and is a key contributor to companion-animal revenue. However, the approval is incremental and does not address the more pressing concerns around U.S. Librela safety perceptions or livestock weakness that have pressured the stock. Competitive dynamics in dermatology remain intense with Merck and Elanco launching rival products, though Zoetis has so far defended its share. Overall, this is a modest positive development that reinforces the quality of the portfolio but is unlikely to shift near-term fundamentals.

Implication

The new product extends the duration of an established therapy, potentially improving compliance and defending against competitive erosion in the dermatology segment. It supports our view that Zoetis's core companion-animal franchises remain strong, but revenue contribution from Cytopoint Plus is likely to be incremental and gradual. The investment thesis still hinges on stabilization of the OA monoclonal antibody franchise and a clearer path to organic growth above 6%. At current valuations near $125, the margin of safety remains thin, and this news does not alter our WAIT rating or attractive entry level around $110. We would need to see sustained OA improvement or a meaningful re-rating of growth expectations before upgrading.

Thesis delta

The investment thesis is unchanged; Cytopoint Plus adds incremental strength to an already healthy dermatology franchise. It does not mitigate the central risks of Librela safety perception or livestock weakness. We maintain WAIT with attractive entry at $110.